We discuss early results from an ongoing study of a triple combination therapy with a PD-L1 checkpoint inhibitor for treating Richter’s transformation.
Discussion of new results from a phase 1 clinical trial of the atezolizumab plus immunogenic chemotherapy. Atezolizumab is a checkpoint inhibitor that blocks PD-L1, a checkpoint protein found on cancer cells. It is already approved for use in treating certain types of bladder cancers and lung cancers.
and President, interviewed Dr. Alexey Danilov, Associate Director of the Toni Stephenson Lymphoma Center at City of Hope in Duarte, CA. They discussed the development of Richter transformation after chimeric antigen receptor T-cell (CAR-T) therapy.
Discussion of a phase 3 clinical trial in progress, investigating the efficacy of the triple combination of ibrutinib plus venetoclax and obinutuzumab with response-dependent discontinuation.
Dr. Mato and Dr. Woyach discusses the results of a study looking at which features might predict the future development of Richter’s syndrome in patients treated with ibrutinib.
CLL and SLL patients with deletion 17p do not respond well to chemoimmunotherapy. But new targeted therapies may help. Zanubrutinib is a next-generation BTK inhibitor being tested in combination with venetoclax for treating patients with deletion 17p. Results from a Phase III trial of this combination were presented at the 2021 ASH meeting.
LLS (Leukemia and Lymphoma Society) has been doing extensive longitudinal research led by Dr. Larry Saltzman on blood cancer patients’ responses to SARS-CoV-2 vaccines.
In this video, Professor Michael Hallek, M.D., the Director of the Center for Integrated Oncology (CIO) at the University of Cologne, Germany, and the head of the German CLL Study Group (GCLLSG) is interviewed by CLL Society founder and Chief Medical Officer, Dr. Brian Koffman, M.D., a retired family physician and a CLL patient. This video was recorded at the 62nd Annual Meeting of the American Society of Hematology, held virtually in December 2020.
At the annual meeting of the American Society of Hematology (ASH) 2020, our own Brian Koffman interviewed Dr. Benjamin Heyman, a hematologist at UC San Diego Health in San Diego, CA. They discussed the monoclonal antibody cirmtuzumab, which targets a novel antigen, ROR1.
